NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
Rhea-AI Summary
NRx Pharmaceuticals (Nasdaq: NRXP) reported that subsidiary HOPE Therapeutics has treated its first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System at clinics in West Palm Beach and Sarasota, Florida.
The AI-guided, sub-millimetric navigation is integrated into outpatient TMS workflows and supports NRx's planned SPARC-TMS trial of NRX-101 with robotic-enabled TMS for depression and suicidality.
Positive
- First Zeta TMS–navigated patients treated at two HOPE clinics in Florida
- AI-powered, sub-millimetric image guidance added to outpatient TMS workflows
- Technology supports planned SPARC-TMS trial of NRX-101 with robotic-enabled TMS
- Deployment strengthens HOPE's interventional psychiatry platform and service offering
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 23 | Technology deployment | Neutral | -3.6% | Partner Zeta reported first Zeta TMS patient treatment at a HOPE clinic. |
| Jun 22 | FDA expanded access | Positive | -2.6% | FDA authorized an expanded access protocol for NRX‑101 with TMS in depression. |
| Jun 05 | Clinical data highlight | Neutral | +2.2% | Company highlighted real‑world evidence comparing IV ketamine and nasal esketamine. |
| Jun 04 | Equity offering close | Negative | +2.2% | Closed $22.3M common stock offering at $3.50 per share including overallotment. |
| Jun 03 | Equity offering pricing | Negative | -12.3% | Priced 5,714,286-share public offering at $3.50 with optional additional shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent NRXP news around FDA and financing has produced mixed reactions, with some positive catalysts met by selling while dilutive offerings have sometimes been absorbed.
Key Terms
tms medical
major depressive disorder medical
hyperbaric oxygen therapy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and Sarasota, Florida, marking the transition from research deployment to active patient care
- AI-powered, sub-millimetric image guidance is now being applied in HOPE's outpatient TMS workflows for patients with Major Depressive Disorder and other CNS conditions
- Milestone advances HOPE's interventional psychiatry platform and aligns with NRx's planned trial of NRX-101 in combination with robotic-enabled TMS in civilian and military treatment facilities (the SPARC-TMS trial).
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", "NRx" or the "Company"), a clinical-stage biopharmaceutical company, today announced that its subsidiary, HOPE Therapeutics, Inc. ("HOPE"), has treated its first patients using Zeta Surgical's FDA-cleared Zeta TMS Navigation System. HOPE has installed Zeta TMS Navigation Systems at its clinics in West Palm Beach and Sarasota, Florida, with Zeta-navigated patient treatments now underway at both locations.
The first treatments mark HOPE's transition from system deployment to active patient care, bringing AI-powered, sub-millimetric image guidance into routine outpatient TMS workflows for patients with Major Depressive Disorder and other neurological conditions. The Zeta TMS Navigation System uses proprietary RealTrack™ technology to provide real-time, markerless image guidance for TMS procedures, applying artificial intelligence and computer vision to register a patient's MRI or CT imaging to their facial anatomy in under two minutes and to continuously track the position of the TMS coil relative to the planned brain target with sub-millimetric accuracy.
"Treating our first patients with the Zeta TMS Navigation System moves the integrated treatment model we are building at HOPE from concept to clinical reality," said Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals and HOPE Therapeutics. "Bringing neurosurgical-grade targeting precision into the outpatient setting is exactly the kind of capability that distinguishes the HOPE network, and it directly supports our planned trial of NRX-101 in combination with robotic-enabled TMS in patients with depression and suicidality. Our goal has always been to deliver measurable remission to patients who have run out of options, and precision-guided TMS is a meaningful step toward that goal."
TMS is a non-invasive therapy used primarily for treatment-resistant depression, which affects approximately one-third of patients with major depressive disorder. It is also used in other neuropsychiatric conditions, including obsessive-compulsive disorder and other disorders involving brain circuit dysfunction. Because TMS is intended to modulate specific brain regions and neural circuits, accurate and repeatable targeting of patient-specific treatment sites is an important component of treatment delivery, which is the gap the Zeta system is designed to address.
The deployment complements HOPE's broader interventional psychiatry platform, which includes ketamine and Spravato® delivery, TMS, Hyperbaric Oxygen Therapy, and other neuroplastic therapies offered across the HOPE network of clinics. It also aligns with NRx's previously announced clinical trial program of NRX-101 (oral D-cycloserine/lurasidone) in combination with robotic-enabled TMS for patients with depression and suicidality, which is planned to be conducted across a leading US academic teaching hospital, three HOPE Therapeutics clinics, and two military treatment facilities.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.
About HOPE Therapeutics
HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals (Nasdaq: NRXP), is a provider of advanced psychiatric and neurological care, specializing in evidence-based treatments for major depressive disorder, anxiety, and other complex neurological conditions. Operating out of state-of-the-art clinics, HOPE Therapeutics focuses on improving patient outcomes through the application of modern medical technologies and clinical practices.
For more information, please visit www.hopetherapeutics.com.
About ZETA SURGICAL
ZETA SURGICAL is redefining the standard of care for image-guided surgery and targeted neuro-therapeutics. Its navigation and robotics platform applies advanced artificial intelligence and computer vision to enable high-accuracy image guidance across virtually any point of care in minutes, unlocking less invasive and more precise targeted therapies. The Zeta Navigation System and Zeta TMS Navigation System are cleared by the FDA and commercially available in the United States.
For more information, please visit www.zetasurgical.com.
Media Contact -- media@zetasurgical.com
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not
place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com
